Nature Communications (Feb 2022)
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
- Jianming Xu,
- Yi Li,
- Qingxia Fan,
- Yongqian Shu,
- Lei Yang,
- Tongjian Cui,
- Kangsheng Gu,
- Min Tao,
- Xiuwen Wang,
- Chengxu Cui,
- Nong Xu,
- Juxiang Xiao,
- Quanli Gao,
- Yunpeng Liu,
- Tao Zhang,
- Yuxian Bai,
- Wei Li,
- Yiping Zhang,
- Guanghai Dai,
- Dong Ma,
- Jingdong Zhang,
- Chunmei Bai,
- Yunchao Huang,
- Wangjun Liao,
- Lin Wu,
- Xi Chen,
- Yan Yang,
- Junye Wang,
- Shoujian Ji,
- Hui Zhou,
- Yan Wang,
- Zhuo Ma,
- Yanqi Wang,
- Bo Peng,
- Jiya Sun,
- Christoph Mancao
Affiliations
- Jianming Xu
- Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital
- Yi Li
- Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital
- Qingxia Fan
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University
- Yongqian Shu
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University
- Lei Yang
- Department of Radiotherapy, Nantong Tumor Hospital
- Tongjian Cui
- Department of Medical Oncology, Fujian Provincial Hospital
- Kangsheng Gu
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University
- Min Tao
- Department of Oncology, The First Affiliated Hospital of Soochow University
- Xiuwen Wang
- Department of Chemotherapy, Qilu Hospital of Shandong University
- Chengxu Cui
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Nong Xu
- Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University
- Juxiang Xiao
- Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University
- Quanli Gao
- Department of Immunotherapy, Henan Cancer Hospital
- Yunpeng Liu
- Department of Oncology, The First Hospital of China Medical University
- Tao Zhang
- Cancer Center, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
- Yuxian Bai
- Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital
- Wei Li
- Cancer Center, The First Hospital of Jilin University
- Yiping Zhang
- Department of Thoracic Oncology, Zhejiang Cancer Hospital
- Guanghai Dai
- Department of Oncology, Chinese People’s Liberation Army General Hospital
- Dong Ma
- Department of Gastrointestinal Oncology, Guangdong Provincial People’s Hospital
- Jingdong Zhang
- Department of Gastroenterology, Liaoning Cancer Hospital
- Chunmei Bai
- Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
- Yunchao Huang
- Department of Thoracic Surgery I, Yunnan Cancer Hospital
- Wangjun Liao
- Department of Oncology, Nanfang Hospital, Southern Medical University
- Lin Wu
- Departmentof Thoracic Medical Oncology, Hunan Cancer Hospital
- Xi Chen
- Department of Oncology, No. 900 Hospital of The Joint Logistic Support Force
- Yan Yang
- Department of Gastrointestinal Oncology, Gansu Provincial Cancer Hospital
- Junye Wang
- Department of Oncology, Affiliated Hospital of Jining Medical University
- Shoujian Ji
- Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital
- Hui Zhou
- Innovent Biologics, Inc.
- Yan Wang
- Innovent Biologics, Inc.
- Zhuo Ma
- Innovent Biologics, Inc.
- Yanqi Wang
- Innovent Biologics, Inc.
- Bo Peng
- Innovent Biologics, Inc.
- Jiya Sun
- Innovent Biologics, Inc.
- Christoph Mancao
- Innovent Biologics, Inc.
- DOI
- https://doi.org/10.1038/s41467-022-28408-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
Patients with advanced esophageal cancer have poor prognosis and limited treatment options. This randomized, phase II trial compares the efficacy and safety of the anti-PD-1 antibody sintilimab versus chemotherapy in Chinese patients with esophageal squamous cell carcinoma after first-line therapy
